Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab in advanced soft tissue and Ewing's sarcoma
NCT00668148Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2008
- Primary completion
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of cixutumumab in Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), rhabdomyosarcoma (RMS), leiomyosarcoma (LMS), Liposarcoma, sponsored by Eli Lilly and Company. Started Jul 2008; status: completed.
02
Drugs
cixutumumab
03
Conditions
Ewing sarcomaperipheral primitive neuroectodermal tumor (pPNET)rhabdomyosarcoma (RMS)leiomyosarcoma (LMS)Liposarcoma
Beyond the preview
Go deeper on NCT00668148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668148.